Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Friday 11:00 am – 12:00 pm Conference Wide Panel: Value Cost Effectiveness: Implications of the Changing Landscape in Reimbursement and Regulations – MassBio Annual Meeting 2014, Royal Sonesta Hotel, Cambridge, MA

Reporter: Aviva Lev-Ari, PhD, RN

Conference Coverage for Scientific and Social Media

Panelists:

Chris Coburn, Vice President, Innovation, Partners HealthCare
Geoff MacKay,President & CEO, Organogenesis
Christina Severin, President & CEO, Beth Israel Deaconess Care Organization

Moderator:

Skip Irving, Partner and Managing Director, Health Advances

in Europe single payer – now push back. Trend to get single payer system n the US. Solutions require engage across the silos.

Chris Coburn, Vice President, Innovation, Partners HealthCare

Cost vs Research, asset consolidation in Healthcare, no more 6,000 Hospitals. Partners is the largest Research in US and the World, NIH cuts felt at Partners. Center for creation of innovations, value is created by innovations.

Imaging cover cost of increments of doing research.yield cost of research, classes of collaborators 11% in Academic Centers, no resources to cover the cost. how to promote innovation to generate revenue from research

Partners thrives to be the BEST in Research and application to Medicine

MassBio innovate in TEN years: engage in upscale BMI.

Decision making index, Clinician have the largest say on treatment,
Geoff MacKay,President & CEO, Organogenesis

Moderator: Why is value so important?

Geoff – Regulatory, longer to get to Agency, less attractive reimbursement, cost containment innovation should not be impaired through Healthcare reform transition. Cost containment – introduce innovation rather then reduce service.

Systems innovation, quality of care and containment of cost, Hospital x measuring cost, value created cost increased. Organogenesis, have a product, dependence on Medicare, Bundling of products, one code for a group of technology. Combination of stem cell with wound dressing, innovative therapies can be abandonment for low tech for reasons of cost containment.

Transparency related to payment needed.

MA has all the players, get it right in MA Single payer system

Health Economics model do not speak for all Payers,though attempts to

CMS have data and decision making pathways, Government Affairs and Economics Department, need to collaborate
Christina Severin, President & CEO, Beth Israel Deaconess Care Organization

ACO – types of ACOs, six hospital 4 risk contracts, +200 MDs, improve quality measure 135 measures, 3 repeats, Cost challenge, healthcare supply drive costs, demand over all increase therefore, cost is been driven up,

Case: Hep C – screen members – risk contract does not allow

ACO – PCPs lead by empowerment, Specialists drive revenues.

Stage One of ObamaCare – get all insured, obesity epidemics – if successful health care cost will decline.

Share decision to increase collaboration with Payers